ArticlePloS one2007
Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays.
Article in PloS one, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 120 citations in OpenAlex.
- Article
- Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912).Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations.Nature communications · 2020Article
- Nuclear Factor-κB Activating Protein Plays an Oncogenic Role in Neuroblastoma Tumorigenesis and Recurrence Through the Phosphatidylinositol 3-Kinase/Protein Kinase B Signaling Pathway.Frontiers in cell and developmental biology · 2020Article
- VCF2CNA: A tool for efficiently detecting copy-number alterations in VCF genotype data and tumor purity.Scientific reports · 2019Article
- Opportunities and challenges of circulating biomarkers in neuroblastoma.Open biology · 2019Review
- Zebrafish as a model to study neuroblastoma development.Cell and tissue research · 2018Review
- Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis.Oncotarget · 2017Article
- Alk and Ltk ligands are essential for iridophore development in zebrafish mediated by the receptor tyrosine kinase Ltk.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- The pre-rRNA processing factor DEF is rate limiting for the pathogenesis of MYCN-driven neuroblastoma.Oncogene · 2017Article
- 11q deletion in neuroblastoma: a review of biological and clinical implications.Molecular cancer · 2017Review
- Genetic susceptibility to neuroblastoma.Current opinion in genetics & development · 2017Review
- Role of microRNAs in epigenetic silencing of the CHD5 tumor suppressor gene in neuroblastomas.Oncotarget · 2016Article
- Article
- Acquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomes.BMC cancer · 2015Article
- Bone marrows from neuroblastoma patients: an excellent source for tumor genome analyses.Molecular oncology · 2015Article
- Translating basic science discoveries to clinical practice-Let us not repeat the naiveté of the pre-omics era.Annals of translational medicine · 2015Article
- Common somatic alterations identified in maffucci syndrome by molecular karyotyping.Molecular syndromology · 2014Article
- The novel kinase inhibitor EMD1214063 is effective against neuroblastoma.Investigational new drugs · 2014Article
- Mapping of the chromosomal amplification 1p21-22 in bladder cancer.BMC research notes · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundNeuroblastomas are characterized by chromosomal alterations with biological and clinical significance. We analyzed paired blood and primary tumor samples from 22 children with high-risk neuroblastoma for loss of heterozygosity (LOH) and DNA copy number change using the Affymetrix 10K single nucleotide polymorphism (SNP) array.
findingsMultiple areas of LOH and copy number gain were seen. The most commonly observed area of LOH was on chromosome arm 11q (15/22 samples; 68%). Chromosome 11q LOH was highly associated with occurrence of chromosome 3p LOH: 9 of the 15 samples with 11q LOH had concomitant 3p LOH (P = 0.016). Chromosome 1p LOH was seen in one-third of cases. LOH events on chromosomes 11q and 1p were generally accompanied by copy number loss, indicating hemizygous deletion within these regions. The one exception was on chromosome 11p, where LOH in all four cases was accompanied by normal copy number or diploidy, implying uniparental disomy. Gain of copy number was most frequently observed on chromosome arm 17q (21/22 samples; 95%) and was associated with allelic imbalance in six samples. Amplification of MYCN was also noted, and also amplification of a second gene, ALK, in a single case.
conclusionsThis analysis demonstrates the power of SNP arrays for high-resolution determination of LOH and DNA copy number change in neuroblastoma, a tumor in which specific allelic changes drive clinical outcome and selection of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.